GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.